$CARA Any reason Vifor / Fresnius wouldn’t make a move on CARA and just acquire it given the extent of their involvement in renal care / dialysis centers? Seems like a no brainer to me. Still cheap at $9. Very cheap IMO. Might not ever get to see sales skyrocket when a PR gets dropped on you. Never know with biotech M&A. Management does suck though like many other bios. It happens. 🤷‍♂️
3
5
5 Likes